Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Monosodium Glutamate (MSG) is the sodium salt of the common amino acid glutamic acid. In a clinical context, it is utilized within various non-standardized food and pollen allergenic extracts for diagnostic and therapeutic purposes in allergy management.
Name
Monosodium Glutamate
Raw Name
MONOSODIUM GLUTAMATE
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Monosodium Glutamate
Monosodium Glutamate (MSG) is the sodium salt of the common amino acid glutamic acid. In a clinical context, it is utilized within various non-standardized food and pollen allergenic extracts for diagnostic and therapeutic purposes in allergy management.
Detailed information about Monosodium Glutamate
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Monosodium Glutamate.
Monosodium Glutamate (MSG), chemically known as the sodium salt of L-glutamic acid, is a naturally occurring non-essential amino acid that serves as a fundamental building block of proteins and a primary excitatory neurotransmitter in the central nervous system. While widely recognized as a flavor enhancer (umami), in the realm of clinical pharmacology and immunology, Monosodium Glutamate is classified under the Established Pharmacologic Class (EPC) as a Non-Standardized Food Allergenic Extract. It also falls under broader categories such as Non-Standardized Pollen Allergenic Extract and Standardized Insect Venom Allergenic Extract when used as a stabilizing agent or a component in diagnostic testing and immunotherapy.
The FDA first recognized MSG as 'Generally Recognized as Safe' (GRAS) in 1958. However, its clinical application in allergenic extracts is governed by strict manufacturing standards to ensure that the protein fractions—which may include glutamate-bound complexes—are consistent for diagnostic skin prick testing (SPT) and subcutaneous immunotherapy (SCIT). Healthcare providers typically utilize these extracts to identify specific sensitivities in patients presenting with 'MSG Symptom Complex,' a condition characterized by a constellation of symptoms following ingestion of the substance.
At the molecular level, Monosodium Glutamate dissociates into sodium ions and glutamate ions upon ingestion or injection. Glutamate is the most abundant excitatory neurotransmitter in the vertebrate nervous system. It acts primarily on two classes of receptors: ionotropic receptors (which include NMDA, AMPA, and kainate receptors) and metabotropic receptors (mGluRs). These receptors are responsible for mediating post-synaptic excitation, neural plasticity, and sensory perception.
In the context of an allergenic extract, Monosodium Glutamate works by interacting with the immune system's IgE (Immunoglobulin E) antibodies. When a small amount of the extract is introduced to the skin during a diagnostic test, it cross-links IgE molecules on the surface of mast cells. This triggers the release of inflammatory mediators like histamine and leukotrienes, resulting in a localized 'wheal and flare' reaction. This reaction allows clinicians to objectively measure a patient's sensitivity to the substance. For therapeutic immunotherapy, the mechanism involves shifting the immune response from a Th2 (allergic) profile to a Th1 (regulatory) profile, increasing the production of IgG4 'blocking' antibodies.
When ingested as a food component, MSG is rapidly absorbed from the gastrointestinal tract via active transport mechanisms shared with other acidic amino acids. Its bioavailability is high, though it undergoes significant 'first-pass' metabolism within the enterocytes (intestinal cells). In clinical diagnostic applications (skin testing), systemic absorption is negligible, as the dose is localized to the epidermis or dermis.
Glutamate does not readily cross the blood-brain barrier (BBB) under normal physiological conditions, despite being a major neurotransmitter. The brain maintains its own glutamate pool through local synthesis. In the systemic circulation, glutamate is distributed widely to the muscles, liver, and other organs where it serves as a metabolic fuel. Protein binding is minimal as it exists primarily as a free amino acid in the plasma.
The metabolism of Monosodium Glutamate is extensive and occurs primarily in the liver and gut mucosa. It is converted to alpha-ketoglutarate via oxidative deamination or transamination, entering the Krebs cycle (citric acid cycle) for energy production. It also serves as a precursor for glutamine and the inhibitory neurotransmitter GABA (gamma-aminobutyric acid).
The half-life of exogenous glutamate in the plasma is relatively short, typically ranging from 20 to 60 minutes. It is primarily eliminated through metabolic conversion into other amino acids or CO2. Renal excretion of intact glutamate is very low, as the kidneys efficiently reabsorb the majority of filtered amino acids to conserve nitrogen.
Monosodium Glutamate, as part of allergenic extracts, is used for:
Monosodium Glutamate is not typically prescribed as a standalone medication but is available in the following clinical formats:
> Important: Only your healthcare provider can determine if Monosodium Glutamate is right for your specific condition.
In clinical diagnostic settings, the dosage of Monosodium Glutamate extracts is highly individualized. For skin prick testing, a single drop of a 1:10 or 1:20 w/v (weight/volume) concentration is typically applied to the volar surface of the forearm.
For oral provocation challenges (to diagnose sensitivity), healthcare providers may use a graduated dosing schedule:
Monosodium Glutamate extracts are used with caution in pediatric populations. Skin testing follows the same protocol as adults, though the number of simultaneous tests may be limited to prevent discomfort. Oral challenges in children are typically calculated based on body weight, often starting at 10-25 mg/kg. It is important to note that many healthcare providers defer MSG sensitivity testing in children until they are at least 6 years of age unless symptoms are severe.
No specific dosage adjustments are required for diagnostic skin testing in patients with renal impairment. However, for oral challenges, patients with end-stage renal disease (ESRD) should be monitored for sodium loading, as MSG contributes to total sodium intake.
Glutamate metabolism is primarily hepatic. While skin testing is unaffected, patients with severe hepatic encephalopathy should avoid high-dose oral challenges, as glutamate can contribute to the nitrogen load and potentially exacerbate ammonia levels.
Elderly patients may have thinner skin, which can lead to more frequent false-positive results in skin testing (dermatographism). Clinicians often use lower concentrations or rely more heavily on negative controls in this population.
When used for diagnostic purposes:
Since Monosodium Glutamate in a clinical context is usually administered as a one-time diagnostic test or during a scheduled immunotherapy session, missed doses are handled by rescheduling the appointment. If you are on an immunotherapy schedule, contact your allergist immediately to determine the appropriate 'step-back' dose to maintain safety.
Signs of an acute 'overdose' or severe reaction to MSG (often associated with very high oral intake) include:
In the event of an accidental large ingestion or a severe systemic reaction during testing, emergency medical services should be contacted immediately. Treatment is primarily supportive, focusing on hydration and symptom management.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
The most frequently reported side effects associated with Monosodium Glutamate, particularly in the context of the 'MSG Symptom Complex,' include:
These symptoms are generally transient and resolve within 2 to 4 hours without medical intervention.
> Warning: Stop taking Monosodium Glutamate and call your doctor immediately if you experience any of these.
There is no robust clinical evidence suggesting that Monosodium Glutamate causes permanent organ damage or long-term health deficits when used according to clinical guidelines. Some observational studies have investigated links between chronic high intake and metabolic syndrome or obesity, but these findings remain controversial and are not directly applicable to the small doses used in clinical extracts. In the context of immunotherapy, long-term use is intended to induce desensitization, which is a beneficial long-term effect.
No FDA black box warnings currently exist specifically for Monosodium Glutamate. However, all Allergenic Extracts (the class MSG belongs to in this context) carry a general warning regarding the risk of severe non-fatal and fatal systemic allergic reactions. These extracts should only be administered by healthcare providers experienced in the treatment of anaphylaxis.
Report any unusual symptoms to your healthcare provider.
Monosodium Glutamate is generally safe for the majority of the population. However, in a clinical diagnostic or therapeutic context, it must be used with caution in individuals who have a history of severe 'Chinese Restaurant Syndrome' or MSG Symptom Complex. Patients should be aware that MSG sensitivity is not a classic IgE-mediated allergy in most cases, but rather a pharmacological intolerance that can still produce significant distress.
No FDA black box warnings for Monosodium Glutamate. However, the class of Allergenic Extracts requires administration in a clinical setting due to the potential for anaphylaxis.
For patients undergoing diagnostic challenges or immunotherapy:
Monosodium Glutamate does not typically impair the ability to drive. However, if a patient experiences 'MSG Symptom Complex' symptoms such as dizziness, drowsiness, or severe headache, they should refrain from operating heavy machinery until the symptoms have fully resolved.
Alcohol may increase the rate of gastric emptying and potentially enhance the absorption of ingested MSG. Furthermore, alcohol can exacerbate flushing and headaches, which may complicate the interpretation of a diagnostic MSG challenge. It is recommended to avoid alcohol for 24 hours prior to clinical testing.
There is no withdrawal syndrome associated with the discontinuation of Monosodium Glutamate. In the case of immunotherapy, stopping treatment abruptly will result in a loss of the desensitization effect over time.
> Important: Discuss all your medical conditions with your healthcare provider before starting Monosodium Glutamate.
There are no absolute drug-drug contraindications that would result in a fatal interaction with Monosodium Glutamate. However, it should not be used in oral challenges for patients currently experiencing an acute asthma exacerbation or those in hypertensive crisis.
For each major interaction, the mechanism typically involves either pharmacodynamic synergy (e.g., additive effects on heart rate) or interference with the diagnostic readout (e.g., antihistamines masking a positive skin test). Management usually involves temporary discontinuation of the interacting agent or close clinical observation.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Monosodium Glutamate extracts should NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients sensitive to Monosodium Glutamate may also show sensitivity to:
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Monosodium Glutamate.
Monosodium Glutamate is classified as FDA Pregnancy Category B (under the old system). Glutamate is a normal constituent of the human body and is present in the placenta. Dietary MSG does not significantly increase fetal exposure because the placenta effectively regulates glutamate transfer to the fetus. However, clinical diagnostic challenges are typically avoided during pregnancy because a severe systemic reaction (anaphylaxis) in the mother could lead to uterine contractions and fetal distress due to lack of oxygen.
Glutamate is a natural component of breast milk; in fact, breast milk is exceptionally high in free glutamate compared to many other mammalian milks. Maternal ingestion of MSG does not significantly alter the concentration of glutamate in breast milk. Clinical testing is generally considered safe for breastfeeding mothers, provided the mother is monitored for reactions.
Monosodium Glutamate extracts are approved for use in children for diagnostic purposes. However, the 'MSG Symptom Complex' is rarely diagnosed in young children, as they may not be able to articulate the subjective symptoms like 'numbness' or 'tingling.' Dosing for oral challenges must be strictly weight-based. Long-term safety of high-dose MSG in infants has not been established, and it is generally avoided in neonatal nutrition.
In older adults, the primary concerns are related to underlying cardiovascular disease. The transient tachycardia (fast heart rate) or blood pressure changes associated with MSG sensitivity may be less well-tolerated in the elderly. Additionally, age-related declines in renal function mean that the sodium load from high-dose MSG challenges should be monitored in patients with heart failure.
Glutamate itself is not cleared renally in significant amounts, so dose adjustments based on GFR (Glomerular Filtration Rate) are not required for the amino acid component. However, the sodium content (approx. 615mg of sodium per 5g of MSG) must be considered for patients on dialysis or those with Stage 4-5 Chronic Kidney Disease.
Since the liver is the primary site for the nitrogen metabolism of glutamate, patients with severe hepatic cirrhosis (Child-Pugh Class C) may have an impaired ability to process large boluses of amino acids. While standard diagnostic doses are safe, massive ingestion could theoretically contribute to hyperammonemia.
> Important: Special populations require individualized medical assessment.
Monosodium Glutamate acts as a source of the L-glutamate anion. Glutamate is the primary excitatory neurotransmitter in the brain, acting on NMDA (N-methyl-D-aspartate), AMPA, and Kainate ionotropic receptors. These receptors control ion channels that allow sodium and calcium to enter the neuron, leading to depolarization. It also acts on eight types of G-protein coupled metabotropic receptors (mGluR1-mGluR8). In the periphery, glutamate receptors are found in the gut, lungs, and skin, which explains the systemic nature of MSG sensitivity symptoms (e.g., bronchoconstriction or flushing).
The dose-response relationship for MSG is non-linear. Most individuals can tolerate up to 3 grams of MSG without any symptoms. Symptoms typically emerge at doses exceeding 3-5 grams in sensitive individuals. The onset of effect for oral MSG is 20-40 minutes, with a duration of action of approximately 2-3 hours. Tolerance does not typically develop; in fact, some patients report increased sensitivity with repeated frequent exposure.
| Parameter | Value |
|---|---|
| Bioavailability | >90% (as free glutamate) |
| Protein Binding | <5% |
| Half-life | 20 - 60 minutes |
| Tmax | 30 - 90 minutes (oral) |
| Metabolism | Hepatic/Intestinal (Transamination) |
| Excretion | CO2 (Exhalation) 70%, Renal <5% |
Monosodium Glutamate is categorized as a Non-Standardized Food Allergenic Extract. It belongs to the broader class of amino acid salts and neurotransmitter precursors. Related substances used in similar diagnostic contexts include Monopotassium Glutamate and various protein hydrolysates.
Medications containing this ingredient
Common questions about Monosodium Glutamate
In a clinical setting, Monosodium Glutamate is primarily used as a component in allergenic extracts for diagnostic testing. Healthcare providers use these extracts to identify individuals who have a specific sensitivity or 'MSG Symptom Complex.' It is also used in controlled oral challenge tests to confirm whether a patient's symptoms are truly caused by MSG ingestion. Furthermore, it may serve as a stabilizing agent in various therapeutic allergenic extracts used for immunotherapy. It is not used as a medication to treat diseases but rather as a tool for diagnosis and allergy management.
The most common side effects, often referred to as the MSG Symptom Complex, include flushing, sweating, and a pressure-like headache. Many patients also report a sensation of numbness or tingling in the mouth, neck, and arms. These symptoms usually appear within 20 to 40 minutes after taking a significant dose and typically last for a few hours. Some people may also experience mild nausea or a racing heart (palpitations). Most of these reactions are mild and do not require specific medical treatment.
It is generally advised to avoid alcohol when undergoing clinical testing with Monosodium Glutamate. Alcohol can increase the absorption rate of MSG and may also cause flushing and headaches on its own, which can make it difficult for your doctor to interpret the results of a diagnostic test. Combining the two may also worsen the severity of a sensitivity reaction. If you are participating in an oral challenge test, your doctor will likely ask you to abstain from alcohol for at least 24 hours. Always follow the specific pre-test instructions provided by your medical facility.
Dietary Monosodium Glutamate is considered safe during pregnancy as it is a natural amino acid that the body processes efficiently. However, elective clinical procedures like MSG skin testing or oral diagnostic challenges are usually postponed until after delivery. This is a precautionary measure because a severe reaction, although rare, could potentially cause stress to the fetus. If you are pregnant, you should discuss your dietary intake and any planned allergy testing with your obstetrician and allergist. There is no evidence that MSG causes birth defects in humans.
When ingested orally during a diagnostic challenge, Monosodium Glutamate is absorbed relatively quickly, with symptoms typically appearing within 20 to 40 minutes. The peak concentration in the blood usually occurs about 30 to 90 minutes after ingestion. If used in a skin prick test, the reaction (a small red bump) usually develops within 15 to 20 minutes. The effects are generally short-lived, with most symptoms resolving completely within 2 to 4 hours as the body metabolizes the glutamate. This rapid onset and clearance make it a useful tool for clinical provocation studies.
Yes, Monosodium Glutamate is not a medication that requires tapering, and there are no withdrawal symptoms associated with stopping its use. In fact, for individuals diagnosed with MSG sensitivity, the primary treatment is the immediate and complete avoidance of added MSG in the diet. If you are receiving immunotherapy that contains MSG as a stabilizer, stopping the treatment will simply mean you are no longer receiving the desensitization benefits. You should always consult with your allergist before stopping any scheduled immunotherapy program to understand how it affects your overall allergy management plan.
Since Monosodium Glutamate is typically used in one-time diagnostic tests or scheduled clinical appointments, a 'missed dose' usually means a missed appointment. If you miss a diagnostic challenge or an immunotherapy session, you should call your healthcare provider's office to reschedule as soon as possible. Do not attempt to 'double up' on MSG intake at home to make up for a missed clinical test. For those on a specific immunotherapy schedule, your doctor will determine if your next dose needs to be adjusted based on the length of the delay.
There is a long-standing debate in nutritional science regarding MSG and weight gain. Some observational studies have suggested a link between high dietary MSG intake and an increased risk of obesity, possibly by affecting appetite regulation or metabolic processes. However, other large-scale studies have failed to find a significant connection. In the context of clinical diagnostic testing, the doses used are far too small and infrequent to have any impact on body weight. If you are concerned about weight gain, it is best to focus on overall diet and exercise rather than the occasional exposure to MSG in a clinical setting.
Monosodium Glutamate can interact with certain medications, so it is important to inform your doctor of everything you are taking. Specifically, drugs like beta-blockers and ACE inhibitors can make allergic-type reactions more severe or harder to treat. Antihistamines must be stopped several days before skin testing because they will block the results. While most common medications do not have a direct chemical interaction with MSG, the physiological effects of MSG (like increased heart rate) might overlap with the side effects of other drugs. Your healthcare provider will review your medication list for safety before any clinical testing.
Monosodium Glutamate itself is a basic chemical compound and is not a branded pharmaceutical drug. In the clinical world, it is available in various 'non-standardized' extract forms produced by different allergenic manufacturing laboratories. These are essentially generic versions of the extract. Because these are 'non-standardized,' the exact concentration of active protein can vary slightly between manufacturers. Your allergist will select a reputable source for diagnostic extracts, but you won't typically find a 'brand name' version of MSG in the same way you would for a drug like Lipitor or Advil.